Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.

ABSTRACT:

Objective

This study investigated the effectiveness of liraglutide 3.0 mg daily in combination with a standardized multidisciplinary intervention on body weight and body composition changes in a real-life setting.

Methods

A prospective, observational cohort study design was used. Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women). Liraglutide treatment was covered by Swiss health insurance. Clinical and biological data were collected at baseline, 4 months, and 10 months. Body composition was assessed by dual-energy x-ray absorptiometry at baseline and 10 months.

Results

At 10 months, mean (SD) percentage weight loss (WL%) was -12.4% (5.5%) or -14.1 (6.6

SUBMITTER: Santini S 

PROVIDER: S-EPMC10107497 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature